GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Gross-Profit-to-Asset %

TheraCryf (FRA:8EV) Gross-Profit-to-Asset % : 15.25% (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. TheraCryf's annualized Gross Profit for the quarter that ended in Sep. 2023 was €0.92 Mil. TheraCryf's average Total Assets over the quarter that ended in Sep. 2023 was €6.02 Mil. Therefore, TheraCryf's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 15.25%.


TheraCryf Gross-Profit-to-Asset % Historical Data

The historical data trend for TheraCryf's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Gross-Profit-to-Asset % Chart

TheraCryf Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.27 - 5.41

TheraCryf Semi-Annual Data
Mar13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 12.80 15.25

Competitive Comparison of TheraCryf's Gross-Profit-to-Asset %

For the Biotechnology subindustry, TheraCryf's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TheraCryf's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TheraCryf's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where TheraCryf's Gross-Profit-to-Asset % falls into.



TheraCryf Gross-Profit-to-Asset % Calculation

TheraCryf's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=0.501/( (11.53+6.998)/ 2 )
=0.501/9.264
=5.41 %

TheraCryf's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=0.918/( (6.998+5.044)/ 2 )
=0.918/6.021
=15.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


TheraCryf Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of TheraCryf's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf (FRA:8EV) Business Description

Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines